|
1
|
Zubeda S, Kaipa PR, Shaik NA, Mohiuddin
MK, Vaidya S, Pavani B, Srinivasulu M, Latha MM and Hasan Q:
Her-2/neu status: A neglected marker of prognostication and
management of breast cancer patients in India. Asian Pac J Cancer
Prev. 14:2231–2235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Podo F, Buydens L, Degani H, Hilhorst R,
Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J,
Monleon D, et al: Triple-negative breast cancer: Present challenges
and new perspectives. Mol Oncol. 4:209–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang W, Wan YW, Allen GI, Pang K,
Anderson ML and Liu Z: Molecular pathway identification using
biological network-regularized logistic models. BMC Genomics. 14
(Suppl 8):S72013. View Article : Google Scholar
|
|
4
|
Lehmann BD, Jovanović B, Chen X, Estrada
MV, Johnson KN, Shyr Y, Moses HL, Sanders ME and Pietenpol JA:
Refinement of triple-negative breast cancer molecular subtypes:
Implications for neoadjuvant chemotherapy selection. PLoS One.
11:e01573682016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Collignon J, Lousberg L, Schroeder H and
Jerusalem G: Triple-negative breast cancer: Treatment challenges
and solutions. Breast Cancer (Dove Med Press). 8:93–107.
2016.PubMed/NCBI
|
|
6
|
Denkert C, Liedtke C, Tutt A and von
Minckwitz G: Molecular alterations in triple-negative breast
cancer-the road to new treatment strategies. Lancet. 389:2430–2442.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mayer IA, Abramson VG, Lehmann BD and
Pietenpol JA: New strategies for triple-negative breast
cancer-deciphering the heterogeneity. Clin Cancer Res. 20:782–790.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lucero CM, Vega OA, Osorio MM, Tapia JC,
Antonelli M, Stein GS, van Wijnen AJ and Galindo MA: The
cancer-related transcription factor Runx2 modulates cell
proliferation in human osteosarcoma cell lines. J Cell Physiol.
228:714–723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Javed A, Barnes GL, Pratap J, Antkowiak T,
Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB and Stein GS:
Impaired intranuclear trafficking of Runx2 (AML3/CBFA1)
transcription factors in breast cancer cells inhibits osteolysis in
vivo. Proc Natl Acad Sci USA. 102:1454–1459. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pratap J, Wixted JJ, Gaur T, Zaidi SK,
Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS
and Lian JB: Runx2 transcriptional activation of Indian Hedgehog
and a downstream bone metastatic pathway in breast cancer cells.
Cancer Res. 68:7795–7802. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taipaleenmäki H, Browne G, Akech J, Zustin
J, van Wijnen AJ, Stein JL, Hesse E, Stein GS and Lian JB:
Targeting of Runx2 by miR-135 and miR-203 impairs progression of
breast cancer and metastatic bone disease. Cancer Res.
75:1433–1444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chai J, Guo D, Ma W, Han D, Dong W, Guo H
and Zhang Y: A feedback loop consisting of
RUNX2/lncRNA-PVT1/miR-455 is involved in the progression of
colorectal cancer. Am J Cancer Res. 8:538–550. 2018.PubMed/NCBI
|
|
13
|
Yu X, Zhao J and He Y: Long non-coding RNA
PVT1 functions as an oncogene in human colon cancer through
miR-30d-5p/RUNX2 axis. J BUON. 23:48–54. 2018.PubMed/NCBI
|
|
14
|
Kang Y, Zhu X, Xu Y, Tang Q, Huang Z, Zhao
Z, Lu J, Song G, Xu H, Deng C and Wang J: Energy stress-induced
lncRNA HAND2-AS1 represses HIF1α-mediated energy metabolism and
inhibits osteosarcoma progression. Am J Cancer Res. 8:526–537.
2018.PubMed/NCBI
|
|
15
|
Zhou J, Lin J, Zhang H, Zhu F and Xie R:
lncRNA HAND2-AS1 sponging miR-1275 suppresses colorectal cancer
progression by upregulating KLF14. Biochem Biophys Res Commun.
503:1848–1853. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang X, Wang CC, Lee WYW, Trovik J, Chung
TKH and Kwong J: Long non-coding RNA HAND2-AS1 inhibits invasion
and metastasis in endometrioid endometrial carcinoma through
inactivating neuromedin U. Cancer Lett. 413:23–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giuliano AE, Connolly JL, Edge SB,
Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ and
Hortobagyi GN: Breast cancer-major changes in the American joint
committee on cancer eighth edition cancer staging manual. CA Cancer
J Clin. 67:290–303. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cristofanilli M, Budd GT, Ellis MJ,
Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ,
Terstappen LW and Hayes DF: Circulating tumor cells, disease
progression, and survival in metastatic breast cancer. N Engl J
Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pratap J, Imbalzano KM, Underwood JM,
Cohet N, Gokul K, Akech J, van Wijnen AJ, Stein JL, Imbalzano AN,
Nickerson JA, et al: Ectopic runx2 expression in mammary epithelial
cells disrupts formation of normal acini structure: Implications
for breast cancer progression. Cancer Res. 69:6807–6814. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sancisi V, Manzotti G, Gugnoni M, Rossi T,
Gandolfi G, Gobbi G, Torricelli F, Catellani F, Faria do Valle I,
Remondini D, et al: RUNX2 expression in thyroid and breast cancer
requires the cooperation of three non-redundant enhancers under the
control of BRD4 and c-JUN. Nucleic Acids Res. 45:11249–11267. 2017.
View Article : Google Scholar : PubMed/NCBI
|
